BR112023020815A2 - Moduladores de receptor de apelina para o tratamento de condições musculares relacionadas à idade. - Google Patents
Moduladores de receptor de apelina para o tratamento de condições musculares relacionadas à idade.Info
- Publication number
- BR112023020815A2 BR112023020815A2 BR112023020815A BR112023020815A BR112023020815A2 BR 112023020815 A2 BR112023020815 A2 BR 112023020815A2 BR 112023020815 A BR112023020815 A BR 112023020815A BR 112023020815 A BR112023020815 A BR 112023020815A BR 112023020815 A2 BR112023020815 A2 BR 112023020815A2
- Authority
- BR
- Brazil
- Prior art keywords
- age
- apelin receptor
- receptor modulators
- treatment
- related muscle
- Prior art date
Links
- 108091008803 APLNR Proteins 0.000 title abstract 6
- 102000016555 Apelin receptors Human genes 0.000 title abstract 6
- 210000003205 muscle Anatomy 0.000 title abstract 4
- 230000003387 muscular Effects 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 2
- 229940075993 receptor modulator Drugs 0.000 abstract 2
- 208000036119 Frailty Diseases 0.000 abstract 1
- 208000010428 Muscle Weakness Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical class NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 abstract 1
- 206010003549 asthenia Diseases 0.000 abstract 1
- 230000036314 physical performance Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
moduladores de receptor de apelina para o tratamento de condições musculares relacionadas à idade. moduladores do receptor de apelina podem aumentar o desempenho físico, baixa progressão de fragilidade relacionada à idade e pode reduzir fraqueza muscular relacionada à idade em pacientes humanos. esta descrição provê métodos para o tratamento de condições musculares pela utilização de uma classe particular de moduladores do receptor de apelina (por exemplo, agonistas). a condição muscular pode ser uma condição muscular relacionada à idade. é também provido um método para a manutenção e/ou aumento da massa muscular e/ou resistência muscular em um indivíduo idoso pela administração do modulador do receptor de apelina. em algumas realizações, o modulador do receptor de apelina (por exempo, agonista) é bge-105 ou um sal farmaceuticamente aceitável deste.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171475P | 2021-04-06 | 2021-04-06 | |
| US202163272419P | 2021-10-27 | 2021-10-27 | |
| PCT/US2022/023732 WO2022216871A1 (en) | 2021-04-06 | 2022-04-06 | Apelin receptor modulators for treating age-related muscle conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023020815A2 true BR112023020815A2 (pt) | 2023-12-12 |
Family
ID=83546523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023020815A BR112023020815A2 (pt) | 2021-04-06 | 2022-04-06 | Moduladores de receptor de apelina para o tratamento de condições musculares relacionadas à idade. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240252493A1 (pt) |
| EP (1) | EP4319873A1 (pt) |
| JP (1) | JP2024513560A (pt) |
| KR (1) | KR20230165832A (pt) |
| AU (1) | AU2022255183A1 (pt) |
| BR (1) | BR112023020815A2 (pt) |
| CA (1) | CA3216236A1 (pt) |
| IL (1) | IL307509A (pt) |
| MX (1) | MX2023011840A (pt) |
| WO (1) | WO2022216871A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240122926A1 (en) * | 2022-09-27 | 2024-04-18 | BioAge Labs, Inc. | Apelin receptor modulators for treating muscle conditions |
| CN117417325B (zh) * | 2023-12-19 | 2024-10-22 | 药康众拓(北京)医药科技有限公司 | 氘代1,2,4-三唑类Apelin受体激动剂药物及用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20180529A1 (es) * | 2015-05-20 | 2018-03-19 | Amgen Inc | Agonistas de triazol del receptor apj |
-
2022
- 2022-04-06 JP JP2023561359A patent/JP2024513560A/ja active Pending
- 2022-04-06 MX MX2023011840A patent/MX2023011840A/es unknown
- 2022-04-06 WO PCT/US2022/023732 patent/WO2022216871A1/en active Application Filing
- 2022-04-06 EP EP22785400.7A patent/EP4319873A1/en active Pending
- 2022-04-06 IL IL307509A patent/IL307509A/en unknown
- 2022-04-06 CA CA3216236A patent/CA3216236A1/en active Pending
- 2022-04-06 AU AU2022255183A patent/AU2022255183A1/en active Pending
- 2022-04-06 BR BR112023020815A patent/BR112023020815A2/pt unknown
- 2022-04-06 KR KR1020237037976A patent/KR20230165832A/ko unknown
- 2022-04-06 US US18/286,070 patent/US20240252493A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022216871A1 (en) | 2022-10-13 |
| KR20230165832A (ko) | 2023-12-05 |
| AU2022255183A1 (en) | 2023-10-26 |
| MX2023011840A (es) | 2024-03-25 |
| IL307509A (en) | 2023-12-01 |
| CA3216236A1 (en) | 2022-10-13 |
| EP4319873A1 (en) | 2024-02-14 |
| JP2024513560A (ja) | 2024-03-26 |
| US20240252493A1 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023020815A2 (pt) | Moduladores de receptor de apelina para o tratamento de condições musculares relacionadas à idade. | |
| Oertel et al. | Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical research | |
| Balakrishnan et al. | The diagnosis and management of adults with spasticity | |
| D'amico et al. | Recovery of neuronal and network excitability after spinal cord injury and implications for spasticity | |
| Kumar et al. | Effectiveness of Maitland Techniques in idiopathic shoulder adhesive capsulitis | |
| Gracies | Pathophysiology of spastic paresis. II: Emergence of muscle overactivity | |
| de Miguel Valtierra et al. | Ultrasound-guided application of percutaneous electrolysis as an adjunct to exercise and manual therapy for subacromial pain syndrome: A randomized clinical trial | |
| Dettori et al. | Early ankle mobilization, part I: the immediate effect on acute, lateral ankle sprains (a randomized clinical trial) | |
| Monaco et al. | Dysregulation of the descending pain system in temporomandibular disorders revealed by low-frequency sensory transcutaneous electrical nerve stimulation: a pupillometric study | |
| Picelli et al. | Is spasticity always the same? An observational study comparing the features of spastic equinus foot in patients with chronic stroke and multiple sclerosis | |
| US20070066996A1 (en) | Modafinil-based neurorehabilitation of impaired neurological function associated with brian injury | |
| Devrimsel et al. | The effects of whirlpool bath and neuromuscular electrical stimulation on complex regional pain syndrome | |
| Esparza et al. | Effects of local ischemic compression on upper limb latent myofascial trigger points: a study of subjective pain and linear motor performance | |
| Sinha et al. | Effectiveness of scapular mobilization versus myofascial release of subscapularis on pain, ROM and function in subjects with chronic frozen shoulder: a comparative study | |
| Gill et al. | Effect of muscle energy technique on pain and function in adhesive capsulitis–an interventional study | |
| Shirzadi et al. | Application of continuous passive motion in patients with distal radius fractures: a randomized clinical trial | |
| Martens et al. | How does spasticity affect patients with disorders of consciousness? | |
| Senthilkumar et al. | A study on effectiveness of therabite exercises to improve the jaw range of motion in trismus among oral cancer patients | |
| de Brito et al. | Challenges and complications of immobility | |
| Patel et al. | To study the effectiveness of Cyriax Mill's manipulation and deep transverse friction versus myofascial release technique on pain, grip strength and functional disability in subjects with lateral epicondylitis: an experimental study | |
| Sai et al. | Effects of Mulligan’s mobilisation with movement on pain and range of motion in diabetic frozen shoulder a randomized clinical trail | |
| Kotagiri et al. | The Effectiveness of Muscle Energy Technique and Mobilization to Improve the Shoulder Range of Motion in Frozen Shoulder. | |
| JP2022544057A (ja) | ニテニン類似体化合物ならびに慢性および急性疼痛の治療におけるそれらの使用 | |
| Aydos et al. | The impact of transcutaneous posterior tibial nerve stimulation in patients with premature ejaculation | |
| Kim | Rehabilitation after hemorrhagic stroke: from acute to chronic stage |